

Literaturliste

Epitheliale Präkursorläsionen – Die orale Leukoplakie

Dr. med. Dr. med. dent. Matthias Kreppel, Barbara Kreppel, Dr. med. Dr. med. dent. Martin Scheer, Priv.-Doz. Dr. med. Uta Drebber, Univ. Prof. Dr. med. Dr. med. dent. Joachim E. Zöller

Oralchirurgie Journal 3/2011

1. Oral leukoplakia related to malignant transformation. *Oral Sci Int* 2006;3:)45-55.
2. Oral premalignant lesions: from a clinical perspective. *Int J Clin Oncol* 2011;16:)5-14.
3. Human papillomavirus and survival of patients with oropharyngeal cancer. *N Engl J Med* 2010;363:(1)24-35.
4. Occurrence of leukoplakia and some other oral white lesions among 20333 adult Swedish people. *Community Dent Oral Epidemiol* 1987;15:(46)51.
5. Follow-up studies in oral leukoplakia. *J Maxillofac Surg* 1977;5:)69-75.
6. Human papillomavirus: its identity and controversial role in oral oncogenesis, premalignant and malignant lesions. *Int J Oncol* 2007;30:(4)813-23.
7. Potentially malignant oral lesions in Northern Ireland: A 20-year population-based perspective of malignant transformation. *Oral Dis* 2001;7:(1)18-24.
8. Aktuelle Klassifikation der Präkursorläsionen des oralen Plattenepithelkarzinoms - Prinzipien der WHO-Klassifikation 2005. *Mund Kiefer GesichtsChir* 2006;10:)89-93.
9. Neoadjuvant radiochemotherapy and radical resection for advanced squamous cell carcinoma of the oral cavity. Outcome of 134 patients. *Strahlenther Onkol* 2008;184:(1)23-9.
10. Gale N, Pilch B, Sidransky D, Westra W, Califano J. Epithelial precursor lesions. World Health Classification of tumours, Pathology and genetics of head and neck tumours. IARC Press, Lyon, 2005:140-3.
11. Clinical applicability of the Ljubljana classification of epithelial hyperplastic laryngeal lesions. *Clin Otolaryngol* 2000;25:)227-32.
12. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. *J Natl Cancer Inst* 2000;92:)709-20.
13. Leukoplakia and incidence of oral cancer. *J Oral Pathol Med* 1989;18:(1)17.
14. Incidence rates of oral cancer and natural history of oral precancerous lesions in a 10-year follow-up study of Indian villagers. *Community Dent Oral Epidemiol* 1980;8:(6)283-333.
15. Epidemiology of cancer by tobacco products and the significance of TSNA. *Crit Rev Toxicol* 1996;26:(2)183-98.

16. Criteria for grading in the Ljubljana classification of epithelial hyperplastic laryngeal lesions. A study by members of the Working Grouping on Epithelial Hyperplastic Laryngeal Lesions of the European Society of Pathology. *Histopathology* 1999;34:)226-33.
17. Long-term treatment outcome of oral premalignant lesions. *Oral Oncol* 2006;42:(5)461-74.
18. Notre classification des hyperplasies de l'épithélium du larynx au point de vue pronostic. *J Fr Otorhinolaryngol Audiophonol Chir Maxillofac* 1971;20:)1145-50.
19. Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. *J Clin Oncol* 2008;26:(3)354-60.
20. Podoplanin expression predicts prognosis in patients with oral squamous cell carcinoma treated with neoadjuvant radiochemotherapy. *Oral Oncol* 2011;in press.
21. Impact of Podoplanin Expression in Oral Squamous Cell Carcinoma: Clinical and Histopathologic Correlations. *Virchows Archiv* 2010;456:(5)473-82.
22. Why oral histopathology suffers inter-observer variability on grading oral epithelial dysplasia: An attempt to understand the sources of variation. *Oral Oncol* 2007;43:)224-31.
23. Evaluation of a new binary system of grading oral epithelial dysplasia for prediction of malignant transformation. *Oral Oncol* 2006;42:)987-93.
24. Relevance of human papilloma virus (HPV) infection to carcinogenesis of oral tongue cancer. *Int J Oral Maxillofac Surg* 2010;39:(7)678-83.
25. Although leukoplakia responds to some treatments relapses and adverse effects are common. *Evid Based Dent* 2005;6:)15-6.
26. Opportunistic screening for oral cancer and precancer in general dental practice: results of a demonstration study. *Br Dent J* 2003;194:)497-502.
27. Malignant transformation in oral leukoplakia. *Scand J Dent Res* 1987;95:)449-55.
28. The convergent development of molecular-targeted drugs for cancer treatment and prevention. *Clin Cancer Res* 2007;13:)4035-41.
29. Systematic review of randomized trials for the treatment of oral leukoplakia. *J Dent Educ* 2002;66:(8)896-902.
30. Differential tissue and subcellular expression of ERM proteins in normal and malignant tissues: cytoplasmic ezrin expression has prognostic significance for head and neck squamous cell carcinoma. *Head Neck* 2006;28:(11)1018-27.
31. An assessment of oral epithelial dysplasia using criteria of Smith and Pindborg's grading system and Ljubljana grading system in oral precancer lesions. *J Oral Maxillofac Pathol* 2004;8:)73-81.
32. Prospective study of alcohol consumption and risk of oral premalignant lesions in men. *Cancer Epidemiol Biomarkers Prev* 2006;15:)774-81.
33. Epidemiologic and histologic study of oral cancer and leukoplakia among 50,915 villagers in India. *Cancer* 1969;24:)832-49.

34. Human papillomavirus as a risk factor for oral squamous cell carcinoma: a meta-analysis, 1982-1997. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2001;91:622-35.
35. Natural history of potentially malignant oral lesions and conditions: an overview of the literature. *J Oral Pathol Med* 2008;37:1-10.
36. Aberrant expression of p53, p16INK4a and Ki-67 as basic biomarker for malignant progression of oral leukoplakias. *J Oral Pathol Med* 2011;DOI 10.1111/j.1600-0714.2011.01026.x.
37. Intraepitheliale Plattenepithelneoplasie (WHO 2005). *HNO* 2009;57:181-8.
38. Epidemiology and correlation of the clinicopathologic features in oral epithelial dysplasia: analysis of 173 cases. *Ann Diagn Pathol* 2011;15:(2)98-102.
39. Studies in oral leukoplakia: a preliminary report on the period prevalence of malignant transformation in leukoplakia based on a follow-up study of 248 patients. *J Am Dent Assoc* 1968;76:(4)767-71.
40. Studies in oral leukoplakias. V. Clinical and histologic signs of malignancy. *Acta Odontol Scand* 1963;21:407-14.
41. Evaluation of COX-2, EGFR and p53 as biomarkers of non-dysplastic oral leukoplakias. *Exp Mol Pathol* 2010;89:(2)197-203.
42. Prognosis of oral premalignant lesions: significance of clinical, histopathological and molecular biological characteristics. *Crit Rev Oral Biol Med* 2003;14:(1)47-62.
43. Oral mucosal lesions in a representative cross-sectional study of aging Germans. *Community Dent Oral Epidemiol* 2000;28:(390)398.
44. Identification of risk groups for oral precancer and cancer and preventive measures. *Clin Oral Invest* 2001;5:207-13.
45. Nichtinvasive Bürstenbiopsie als innovative Methode in der Früherkennung des Mundhöhlenkarzinoms. *Mund Kiefer GesichtsChir* 2004;8:229-36.
46. Expression of cyclo-oxygenase-2 in human tongue carcinoma and its precursor lesions. *Virchows Arch* 2002;440:(6)594-87.
47. Expression of cyclo-oxygenase-2 in human tongue carcinoma and its precursor lesions. *Virchows Arch* 2002;440:(6)594-87.
48. A review of nonsurgical treatment of oral leukoplakia. *Int J Dent* 2010;doi:10.1155/2010/186018.
49. The effect of joint exposure to alcohol and tobacco on risk of cancer of the mouth and pharynx. *J Chronic Dis* 1972;25:(12)711-6.
50. p53 Overexpression, Alone and in Combination with other Biomarkers, Predicts the Development of Oral Cancer in Patients with Leukoplakia. *Clin Cancer Res* 2010;pub ahead of front.
51. Development of squamous cell carcinoma from pre-existent oral leukoplakia: with respect to treatment modality. *Int J Oral Maxillofac Surg* 2011;30:(1)49-53.

52. Autofluorescence imaging of potentially malignant mucosa lesions. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2011;111:(5)568-77.
53. Chemoprevention of oral squamous cell carcinomas. *Onkologie* 2004;27:(2)187-93.
54. Orale Leukoplakien beim manifesten Plattenepithelkarzinom. *Mund Kiefer GesichtsChir* 1998;2:)326-30.
55. Malignant transformation of oral leukoplakia: a follow-up study of a hospital-based population of 166 patients with oral leukoplakia from The Netherlands. *Oral Oncol* 1998;34:(4)270-5.
56. Concomitant leukoplakia in patients with oral squamous cell carcinoma. *Oral Dis* 1999;5:)206-9.
57. A proposal for a classification and staging system for oral leukoplakia: a preliminary study. *Eur J Cancer B Oral Oncol* 1995;32B:(6)396-8.
58. Risk factors for leukoplakia and malignant transformation to oral carcinoma: a leukoplakia cohort of Taiwan. *Br J Cancer* 2000;82:(11)1871-4.
59. Oral leukoplakia and malignant transformation: a follow-up study of 257 patients. *Cancer* 1984;53:)563-8.
60. The pathology of oral cancer and precancer. *Current Diagnostic Pathology* 1996;3:)165-76.
61. Comparative molecular and histological grading of epithelial dysplasia of the oral cavity and the oropharynx. *J Pathol* 2003;199:)354-60.
62. Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management. *Oral Oncol* 2009;45:(4-5)317-23.
63. Potentially malignant disorders of the oral and oropharyngeal mucosa; present concepts of management. *Oral Oncol* 2010;46:)423-5.
64. Oral Leukoplakia: A Proposal for uniform reporting. *Oral Oncol* 2002;38:)521-6.
65. Oral proliferative verrucous leukoplakia revisited. *Oral Oncol* 2008;44:)719-21.
66. p53 Expression in leukoplakia and carcinoma of the oral tongue. *Int J Biol Markers* 2006;21:(2)74-80.
67. Oral health risks of tobacco use and effects of cessation. *Int Dent J* 2010;60:(1)7-30.
68. Nomenclature and classification of potentially malignant disorders of the oral mucosa. *J Oral Pathol Med* 2007;36:)575-80.
69. Oral epithelial dysplasia classification systems: predictive value, utility, weakness and scope for improvement. *J Oral Pathol Med* 2008;37:)127-33.
70. Malignant transformation of oral leukoplakia: a retrospective cohort study of 218 chinese patients. *BMC Cancer* 2010;10:)685.
71. The potential role of podoplanin in tumour invasion. *Br J Cancer* 2007;96:(1)1-5.

72. Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. *Cancer Cell* 2006;9:(4)261-72.
73. Current status and prospects of chemoprevention in oral squamous epithelial carcinomas and precancerous lesions. *Mund Kiefer GesichtsChir* 2004;4:(Suppl 1)160-8.